{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-009206","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.519761+00:00","generated_at":"2026-06-27T04:44:13.392705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OptimizeRx Q4 revenue $20.3M (+24% YoY), FY revenue $61.3M (+42%), guides FY22 $80-85M","bullets":["Q4 GAAP net income $0.6M ($0.04 diluted EPS); non-GAAP net income $4.0M ($0.22 diluted EPS).","Gross margin improved to 61% in Q4 from 52.4% a year ago.","Introduced KPIs: avg revenue per top-20 pharma client $2.5M, 95% penetration, net revenue retention 127%.","FY22 guidance: revenue $80-85M (+31-39% YoY), gross margin 57-60%.","Cash and equivalents $84.7M at Dec 31, 2021; cash flow positive from operations $0.7M in FY21."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-009206","json":"https://secwatch.observer/filing/0001213900-22-009206.json","markdown":"https://secwatch.observer/filing/0001213900-22-009206.md","text":"https://secwatch.observer/filing/0001213900-22-009206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/0001213900-22-009206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022009206/ea156150-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:44:13.392705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}